Caicun Zhou, MD, PhD – Tongji University Shanghai Pulmonary Hospital
Sunvozertinib established itself as the leading targeted therapy for NSCLC patients with EGFR Exon20ins mutations, demonstrating unprecedented response rates and potential for first-line treatment.
Sunvozertinib, a targeted therapy, has emerged as a “Best-in-Class” treatment for non-small cell lung cancer (NSCLC) patients with EGFR Exon20 insertion (Exon20ins) mutations, which typically have poor outcomes. The drug has shown remarkable efficacy, with an objective response rate (ORR) of 60.8% in the second-line setting and beyond. Additionally, sunvozertinib demonstrated a high ORR of 77.8% in treatment-naive patients, indicating its potential as a superior therapeutic option. These findings highlight the promise of sunvozertinib in addressing EGFR Exon20ins mutations and its potential impact in the field of NSCLC treatment.